JUN 0 1 2004

PTO/SB/21 (05-03)

	JUN U 1 ZOUR SE			nt and Tra	pproved for use through 04/30/2003. OMB 0651-0031 demark Office; U.S. DEPARTMENT OF COMMERCE			
Under the Raperwork Reduction Act of 1995, no persons			s are required to respond to a collection Application Number		n of information unless it displays a valid OMB control number.  10/724,857  December 1, 2003  Donald E. Frail			
	TRANSMITTAL	Filing Date I						
	FORM							
(to	(to be used for all correspondence after initial filing)		Art Unit					
			Examiner Name					
Tota	al Number of Pages in This Submission		Attorney Docket Number	01459	O.US1			
		ENC	LOSURES (Check all that	46-1				
		ENC	LOSURES (Check all that	t apply)	After Allowance communication			
	Fee Transmittal Form	╽╚┛╵	Drawing(s)		to Group			
	Fee Attached		Licensing-related Papers	!	Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group			
	Amendment/Reply		Petition		(Appeal Notice, Brief, Reply Brief)			
	After Final		Petition to Convert to a Provisional Application		Proprietary Information			
	Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Addr	2000	Status Letter			
	Extension of Time Request		Terminal Disclaimer	633	Other Enclosure(s) (please Identify below):			
	Express Abandonment Request		Request for Refund		A return-receipt postcard is enclosed.			
	Information Disclosure Statement		CD, Number of CD(s)					
	Certified Copy of Priority Document(s)	Rema	rks					
	Response to Missing Parts/ Incomplete Application							
	Response to Missing Parts under 37 CFR 1.52 or 1.53							

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm or Individual name Pharmacia & Upjohn Company Signature Date May 28, 2004

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Julie K. Lyons		
Signature	Kelie K. Lagors	Date	May 28, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

				Atty. Docket No.			Serial No.		
			01459.US1			10/724,857			
LISTA	_ \	ERENCES CITE	D BY APPLICANT						
	ري د دومد	.)		Applicant	Donald E. l	Frail et a	<u> </u>		
U.S. PA			Filing Date 12/01/2003			Group			
TA TR	EN.		U.S. PA	ATENT DOCUME	ENTS				
Examiner Initial	miner Document		Date	Name Class		Class	Subclass	Filing Date If Appropriate	
	1	Dogument	FOREIGN	PATENT DOCUMENTS			Subclass		
	Document Number		Date	Country		Class	Subclass	Translation	
								Yes	No
	AA	WO 01/32624	November 3, 2000	World		C07D	217/04		
		(	OTHER PRIOR ART (Inc	cluding Author, Title,	Date, Pertinent P	ages, Etc.)			
	AB	B G.Stille, Arzn. Forsch. 14, 534-537, 1964							
	AC	S. Diamond, et al," Chronic tension headache treated with amitruptyline: a double blind study", Headache 11:110-116, 1971							
	AD	T. Higuchi and V. Stella, "Pro-drugs as Novel Drug Delivery Systems", Vol 14 of the A.C.S. Symposium Series, American Chemical Society, 1974							
	AE	J.R. Couch, et al.," Amitriptyline in the prophylaxis of migraine", Neurology 26:121-127, 1976							
	AF	S. M. Berge, et al, "Pharmaceutical Salts," J. Pharm. Sci, 66: P.1-19 (1977)							
	AG	N. Nakeya et al , Chem Pharm. Bull., , 32, P.692, 1984							
	AH	"Remington's Pharmaceutical Sciences", 17th ed., Mack Publishing Company, Easton, PA, 1985							
	AI H. Bundgaard, "Design of Prodrugs", Ed., Elsevier, 1985  AJ K. Widder et al, "Methods in Enzymology", , Ed., Academic Press, 421, P.309-396, 1985								
	AK	Edward B. Roche, "Bioreversible Carriers in Drug Design", American Pharmaceutical Association and Pergamon Press, 1987							
	AL	Journal of Pharmaceutical Sciences, 77, P. 285, 1988							
	AM	"Design and Applications of Prodrugs" P. 113-191, 1991							
	AN	H. Bundgard Advanced Drug Delivery Reviews, , 8, P. 1-38, 1992							
	AO	E. Shen, GM Cooke, RA Horlick, Gene 156: 235-239, 1995							
				<u>,</u>					
Examiner				Date Considere	ed				